CAR T cells in skin cancer: From experimental promise to clinical translation

Cellular therapy is entering a new phase in solid tumors. For dermato-oncology, this shift is no longer theoretical: tumor-infiltrating lymphocyte (TIL) therapy is approved in the United States, and PRAME-directed T cell receptor (TCR) T cells provide the leading receptor-defined benchmark for melanoma. Chimeric antigen receptor (CAR) T cell therapy has entered early-phase clinical evaluation for melanoma and cutaneous lymphomas, with ongoing trials targeting GD2, IL13Rα2, NG2, DLL3, and CD30. Early clinical findings support the feasibility of this approach, demonstrate CAR T cell trafficking to tumor sites, and indicate an acceptable safety profile. The clinical challenge is therefore not conceptual but translational: selecting sufficiently tumor-restricted surface antigens, overcoming antigen heterogeneity, improving trafficking and persistence, and combining CAR T cells rationally with checkpoint blockade, targeted therapy, radiotherapy, or oncolytic strategies. This article summarizes the current clinical landscape and proposes a practical path toward biomarker-selected, combination-ready CAR T cell trials in advanced skin cancer.

Authors

Institutions

Publication Details

Journal
JDDG Journal der Deutschen Dermatologischen Gesellschaft
Published
2026-11-17
DOI
https://doi.org/10.1111/ddg.70578
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

CAR T cells in skin cancer: From experimental promise to clinical translation

Uğur Uslu
JDDG Journal der Deutschen Dermatologischen Gesellschaft
CAR-T cell therapy research
article

CAR T cells in skin cancer: From experimental promise to clinical translation

Uğur Uslu
article en

Abstract

Cellular therapy is entering a new phase in solid tumors. For dermato-oncology, this shift is no longer theoretical: tumor-infiltrating lymphocyte (TIL) therapy is approved in the United States, and PRAME-directed T cell receptor (TCR) T cells provide the leading receptor-defined benchmark for melanoma. Chimeric antigen receptor (CAR) T cell therapy has entered early-phase clinical evaluation for melanoma and cutaneous lymphomas, with ongoing trials targeting GD2, IL13Rα2, NG2, DLL3, and CD30. Early clinical findings support the feasibility of this approach, demonstrate CAR T cell trafficking to tumor sites, and indicate an acceptable safety profile. The clinical challenge is therefore not conceptual but translational: selecting sufficiently tumor-restricted surface antigens, overcoming antigen heterogeneity, improving trafficking and persistence, and combining CAR T cells rationally with checkpoint blockade, targeted therapy, radiotherapy, or oncolytic strategies. This article summarizes the current clinical landscape and proposes a practical path toward biomarker-selected, combination-ready CAR T cell trials in advanced skin cancer.

JDDG Journal der Deutschen Dermatologischen Gesellschaft
Universitätsklinikum Würzburg (DE)
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon